Effects of adenine arabinoside on serum and intrahepatic replicative forms of duck hepatitis B virus in chronic infection

Katsutaro Hirota, Averell H. Sherker, Masao Omata, Osamu Yokosuka, Kunio Okuda – 1 January 1987 – Adenine arabinoside is an antiviral agent which has been used in a number of clinical studies for the treatment of chronic infections with hepatitis B virus. In order to better understand its effects and mode of action, we treated ducks chronically infected with duck hepatitis B virus with a 2‐week course and monitored the effects of the drug on viral replication by studying duck hepatitis B virus DNA in liver and serum using molecular biological techniques.

The influence of HTLV‐III infection on the natural history of hepatitis B virus infection in male homosexual HBsAg carriers

Kim Krogsgaard, Bjarne ÖRskov Lindhardt, Jens Ole Nielsen, Poul Andersson, Peter Kryger, Jan Aldershvile, Jan Gerstoft, Court Pedersen – 1 January 1987 – The presence of antibodies to HTLV‐III and markers of active hepatitis B virus replication was examined in a longitudinal study of 33 consecutive male homosexual HBsAg carriers. The mean follow‐up time was 37 months (range = 4 to 109 months). All patients were initially hepatitis B virus DNA‐positive and HBeAg positive. Antibodies to HTLV‐III were detectable in eight patients while they were positive for both of these markers.

δ‐Infection and suppression of hepatitis B virus replication in chronic HBsAg carriers

Kim Krogsgaard, Peter Kryger, Jan Aldershvile, Poul Andersson, Thorkild I. A. Sørensen, Jens Ole Nielsen, The Copenhagen Hepatitis Acuta Programme – 1 January 1987 – The presence of hepatitis B virus DNA and anti‐δ was examined in a longitudinal study of 24 patients known to be δ‐infected during the course from acute to chronic hepatitis B virus infection. Fifteen patients (63%) were hepatitis B virus DNA positive in the first serum sample. Eleven of 14 patients, who cleared hepatitis B virus DNA, did so following or at the same time as onset of δ‐infection.

Purification and physical‐chemical characterization of hepatic stimulator substance

Douglas R. Labrecque, Gregory Steele, Steven Fogerty, Michelle Wilson, James Barton – 1 January 1987 – Hepatic stimulator substance is a liver growth stimulator derived from the hepatocyte cytosol of weanling or regenerating adult rat livers. The present paper reports the almost 9,000‐fold purification of hepatic stimulator substance with an approximately 100,000‐fold increase in specific growth stimulator activity.

Compensated cirrhosis: Natural history and prognostic factors

Pere Ginés, Enrique Quintero, Vicente Arroyo, Josep Terés, Miguel Bruguera, Antoni Rimola, Joan Caballería, Joan Rodés, Ciril Rozman – 1 January 1987 – To investigate the natural history of compensated cirrhosis, 293 consecutive patients without previous major complications (ascites, jaundice, encephalopathy or gastrointestinal hemorrhage) were studied in terms of morbidity (probability of developing decompensated cirrhosis during follow‐up) and survival. Patients were diagnosed by liver histology between 1968 and 1980. Median follow‐up was 63 months.

Subscribe to